Phase 2b trial of inhaled imatinib for treatment of pulmonary arterial hypertension

20260 citationsJournal Articlegreen Open Access

Authors

N.S. Hill · Tufts Medical Center

Hunter Gillies · NKT Therapeutics (United States)

Murali M Chakinala · Washington University in St. Louis

Jeremy P Feldman · Memorial Hospital of South Bend

Marius M Hoeper · Medizinische Hochschule Hannover

Zhi-Cheng Jing · Guangdong Academy of Medical Sciences

V Mclaughlin

Abstract

Add-on dry powder inhaled imatinib (AV-101) was not effective in lowering PVR at any of the studied doses in patients with PAH. The phase 3 part of the IMPAHCT study was halted.

Topics & Keywords

Pulmonary Hypertension Research and Treatments Chronic Myeloid Leukemia Treatments Heart rate and cardiovascular health

Publication Details

Published in: American Journal of Respiratory and Critical Care Medicine

DOI: 10.1093/ajrccm/aamaf128

Field-Weighted Citation Impact: 0.00

Command Palette

Phase 2b trial of inhaled imatinib for treatment of pulmonary arterial hypertension

Authors

Abstract

Topics & Keywords

Publication Details